Reclaiming
tissue tranquility

Clinical Trials

Following the encouraging results from our previously announced Phase 1b/2 trial of Resolaris in patients diagnosed with adult FSHD, our 002 trial, we continued to enroll patients across our ongoing clinical studies for three different types of rare myopathies with an immune component:

  • Facioscapulohumeral muscular dystrophy (FSHD)
  • Early onset FSHD
  • Limb-girdle muscular dystrophy 2B

The primary objectives of these studies are to establish a safety and tolerability database and to explore and establish activity signals, such as various functional endpoints and biomarkers, which will best inform our clinical development path forward, including endpoints for a Biologics License Application (BLA).

Ongoing Clinical Trials

 

Early Onset FSHD (003) Trial: Phase 1b/2 »

In the fourth quarter of 2015, we initiated a multinational, multi-center Phase 1b/2 clinical trial of Resolaris in patients with early onset FSHD.  This international Phase 1b/2 clinical trial is an open-label, intra-patient dose escalation study designed to assess the safety, tolerability, immunogenicity and biological activity of Resolaris at weekly doses of 0.3, 1.0 and 3.0 mg/kg to patients with early onset FSHD.

Study protocol is to enroll 8 patients between the ages of 16 and 25 and 8 patients between the ages of 12 and 15.

Stage 1 completed enrollment in August 2016. We announced interim data from our first four patients enrolled in Stage 1 in the fourth quarter of 2016.

More Info

First Extension (005) Trial: Phase 1b/2 »

In the third quarter of 2015, we initiated a long-term extension study for patients from our 002 Study.  This multinational, multi-center, open-label extension study is designed to assess the long-term safety, effects on muscle, pharmacodynamic (PD) and systemic exposure of Resolaris in adult FSHD patients from our 002 Study.  Eligible patients in jurisdictions where this trial is approved have the opportunity to receive weekly doses of 3.0 mg/kg until Resolaris receives regulatory approval or the program is discontinued.

We announced an update from these patients in the fourth quarter 2016.

More Info

Second Extension (006) Trial: Phase 1b/2 »

In the second quarter of 2016, we initiated a long-term extension study for patients from our 003 and 004 studies.  This multinational, multi-center, open-label extension study is designed to assess the long-term safety, effects on muscle, PD and systemic exposure of Resolaris in adult FSHD, early-onset FSHD, and LGMD2B patients from our 003 and 004 studies.

More Info

Completed Clinical Trials

LGMD2B/FSHD (004) Trial: Phase 1b/2 »

In the fourth quarter of 2015, we initiated a multinational, multi-center Phase 1b/2 clinical trial of Resolaris in adult patients with LGMD2B or FSHD.  This international Phase 1b/2 clinical trial is an open-label, intra-patient dose escalation study designed to assess the safety, tolerability, immunogenicity and biological activity of weekly and twice weekly intravenous infusions of Resolaris in adults with either LGMD2B or FSHD.

We completed enrollment ahead of schedule in May of 2016 with 18 total patients (8 with FSHD and 10 with LGMD), exceeding our stated target enrollment of 16 patients.

We announced results in the fourth quarter of 2016.

More Info

FSHD (002) Trial: Phase 1b/2 »

In March of 2016, we announced results from our multi-national exploratory Phase 1b/2 clinical trial of Resolaris in adult patients with FSHD in the United States and European Union. This randomized, double-blind, placebo-controlled trial was designed to evaluate the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics markers and clinical assessments of multiple intravenous doses of Resolaris in adults with FSHD.

Resolaris was studied in three dose escalation cohorts (0.3, 1.0 and 3.0 mg/kg) across four sites and 20 patients.  In each cohort, patients were randomized at a ratio of 3:1 to receive Resolaris or placebo.  Patients in the first two cohorts were dosed weekly over a period of one month, and patients in the third cohort were dosed weekly over a period of three months.

We believe the safety, tolerability, immunogenicity and activity profile of Resolaris as demonstrated in this study warrants advancing our program in adult FSHD patients and potentially other rare diseases.

More Info

Healthy Subjects (001) Study:  Phase 1 »

In the first quarter of 2014, we completed a double-blind, placebo-controlled Phase 1 clinical trial of Resolaris, in which we assessed its safety and tolerability in 32 healthy subjects. Resolaris was shown to be well tolerated at all doses tested, and no serious adverse events were reported. Based on the favorable clinical safety, pharmacokinetic and immunogenicity profile of Resolaris in this trial, we decided to advance Resolaris into clinical trials of RMIC patients.

 
© 2007 - 2017   aTyr Pharma.   Legal   Privacy Policy